All In Biotech

Drug Trial Radar · NCT03566238

This Study Will Investigate the Efficacy and Safety of A4250 in Children With PFIC Types 1 or 2

A Double-Blind, Randomized, Placebo-Controlled, Phase 3 Study to Demonstrate Efficacy and Safety of A4250 in Children With Progressive Familial Intrahepatic Cholestasis Types 1 and 2 (PEDFIC 1)

Last checked: Nov 20, 2026Latest source record: Nov 28, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

62

Actual

Start

May 16, 2018

Primary completion

Jul 27, 2020

Study completion Jul 28, 2020

Sponsor

Lead sponsor
AlbireoIndustry
Sponsor type
Industry
First posted
Jun 25, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 6 months, up to 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Double blind, randomized, placebo controlled, Phase 3 study to investigate the efficacy and safety of low doses and high doses of A4250 compared to placebo in children with progressive familial intrahepatic cholestasis (PFIC) types 1 and 2.

Conditions

  • PFIC1
  • PFIC2

Interventions

  • A4250 (odevixibat)Drug

    A4250 is a small molecule and selective inhibitor of ileal bile acid transporter (IBAT).

  • PlaceboDrug

    Placebo identical in appearance to active drug (A4250).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With at Least a 70% Reduction in Fasting Serum Bile Acid (s-BA) Concentration From Baseline to the End of Treatment or Reaching a Level <=70 Micromoles Per Liter (Mcmol/L) After 24 Weeks of TreatmentTime frame: From Baseline (Day 1) up to Week 24
  2. Percentage of Positive Pruritus Assessments at the Participant Level Based on the Albireo Observer-Reported Outcome (ObsRO) Instrument Over the 24-Week Treatment PeriodTime frame: From Baseline (Day 1) up to Week 24

Locations

45 sites in 15 countries. Site status is shown where the registry gives one.

  • Children's Hospital Los Angeles

    Los Angeles, California

  • University of California, San Francisco

    San Francisco, California

  • Children's Hospital Colorado

    Denver, Colorado

  • Emory University School of Medicine

    Atlanta, Georgia

  • Johns Hopkins School of Medicine

    Baltimore, Maryland

  • Washington University School of Medicine

    St Louis, Missouri

  • Icahn School of Medicine at Mount Sinai

    New York, New York

  • Columbia University Medical Center - Presbyterian Hospital Building

    New York, New York

  • Cleveland Clinic

    Cleveland, Ohio

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania

  • Children's Hospital of Pittsburgh

    Pittsburgh, Pennsylvania

  • Baylor College of Medicine - Texas Children's Liver Center

    Houston, Texas

  • The Royal Children's Hospital

    Melbourne, Australia

  • UZ Leuven

    Leuven, Belgium

  • Cliniques Universitaires Saint-Luc

    Woluwe-Saint-Lambert, Belgium

  • The Hospital for Sick Children

    Toronto, Canada

  • British Columbia Children's Hospital

    Vancouver, Canada

  • University and Pediatric Hospital of Lyon

    Bron, France

  • Universite Paris SUD - Hopitaux Universitaires Paris-Sud - Hopital Bicetre

    Le Kremlin-Bicêtre, France

  • Hospital de la Timone

    Marseille, France

  • Hospital Necker-Enfants maladies

    Paris, France

  • Uniklinikum Essen- Kinderklinik II

    Essen, Germany

  • Medizinische Hochschule Hannover

    Hanover, Germany

  • Kinderklinik Tübingen, Universitätsklinikum Tübingen

    Tübingen, Germany

  • Rambam Medical Centre

    Haifa, Israel

  • Shaare-Zedek Mc

    Jerusalem, Israel

  • Schneider Children's Medical Center Of Israel

    Petah Tikva, Israel

  • Azienda Ospedaliera Papa Giovanni XXIII

    Bergamo, Italy

  • University Hospital Of Padova

    Padova, Italy

  • Ospedale Regina Margherita

    Torino, Italy

  • University Medical Center Groningen

    Groningen, Netherlands

  • Universitair Medisch Centrum (UMC) Utrecht

    Utrecht, Netherlands

  • Instytut Pomnik - Centrum Zdrowia Dziecka

    Warsaw, Poland

  • King Faisal Specialist Hospital & Research Centre

    Riyadh, Saudi Arabia

  • Hospital Universitari Vall d'Hebron

    Barcelona, Spain

  • Hospital Universitario La Paz

    Madrid, Spain

  • Astrid Lindgren Children's Hospital, Karolinska University Hospital

    Solna, Sweden

  • Gazi University

    Ankara, Turkey (Türkiye)

  • Hacettepe University Faculty of Medicine

    Ankara, Turkey (Türkiye)

  • Akdeniz University

    Antalya, Turkey (Türkiye)

Showing 40 of 45 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.